These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 22650223

  • 1. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
    Home P.
    Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S, Jolly G, Horblitt A, Sanaani A, Aronow WS.
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [Abstract] [Full Text] [Related]

  • 3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ, Bailey CJ.
    Drugs; 2005 Nov; 65(3):385-411. PubMed ID: 15669880
    [Abstract] [Full Text] [Related]

  • 4. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
    Ferrannini E, DeFronzo RA.
    Eur Heart J; 2015 Sep 07; 36(34):2288-96. PubMed ID: 26063450
    [Abstract] [Full Text] [Related]

  • 5. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M, Vitale V, Ambrosio ML, Bartoli N, Toffanello G, Ragghianti B, Monami F, Marchionni N, Mannucci E.
    Adv Ther; 2012 Sep 07; 29(9):736-46. PubMed ID: 22923161
    [Abstract] [Full Text] [Related]

  • 6. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH.
    Clin Ther; 2016 Jun 07; 38(6):1288-1298. PubMed ID: 27210264
    [Abstract] [Full Text] [Related]

  • 7. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT, Chang KC, Li CY, Wu JS.
    Cardiovasc Diabetol; 2016 Mar 01; 15():41. PubMed ID: 26932742
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F, Lüscher TF.
    Am J Med; 2017 Jun 01; 130(6S):S18-S29. PubMed ID: 28526186
    [Abstract] [Full Text] [Related]

  • 9. Oral combination therapy in primary care.
    Kalra S, Gupta Y.
    J Pak Med Assoc; 2015 May 01; 65(5):574-5. PubMed ID: 26028398
    [Abstract] [Full Text] [Related]

  • 10. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
    Berkowitz SA, Krumme AA, Avorn J, Brennan T, Matlin OS, Spettell CM, Pezalla EJ, Brill G, Shrank WH, Choudhry NK.
    JAMA Intern Med; 2014 Dec 01; 174(12):1955-62. PubMed ID: 25347323
    [Abstract] [Full Text] [Related]

  • 11. Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.
    Azim S, Baker WL, White WB.
    Curr Cardiol Rep; 2014 Nov 01; 16(11):541. PubMed ID: 25303895
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
    Chang YC, Chuang LM, Lin JW, Chen ST, Lai MS, Chang CH.
    Diabet Med; 2015 Nov 01; 32(11):1460-9. PubMed ID: 25970814
    [Abstract] [Full Text] [Related]

  • 13. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
    Nassif ME, Kosiborod M.
    Am J Cardiol; 2019 Dec 15; 124 Suppl 1():S12-S19. PubMed ID: 31741435
    [Abstract] [Full Text] [Related]

  • 14. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
    Seong JM, Choi NK, Shin JY, Chang Y, Kim YJ, Lee J, Kim JY, Park BJ.
    PLoS One; 2015 Dec 15; 10(5):e0124287. PubMed ID: 25992614
    [Abstract] [Full Text] [Related]

  • 15. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS, Steinke DT, Rutter MK, Emsley RA, Ashcroft DM.
    Diabetes Obes Metab; 2016 Sep 15; 18(9):916-24. PubMed ID: 27177784
    [Abstract] [Full Text] [Related]

  • 16. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U, Pop-Busui R, Eagle KA.
    Ann Pharmacother; 2008 Oct 15; 42(10):1466-74. PubMed ID: 18698014
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F, Lüscher TF.
    Am J Cardiol; 2017 Jul 01; 120(1S):S17-S27. PubMed ID: 28606340
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1.
    Yandrapalli S, Jolly G, Horblitt A, Pemmasani G, Sanaani A, Aronow WS, Frishman WH.
    Cardiol Rev; 2020 Jul 01; 28(4):177-189. PubMed ID: 32282393
    [Abstract] [Full Text] [Related]

  • 19. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J.
    Am J Cardiol; 2017 Jul 01; 120(1S):S4-S16. PubMed ID: 28606343
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL, Davis TME.
    Clin Ther; 2017 May 01; 39(5):1012-1025. PubMed ID: 27863704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.